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Background: Human T-cell leukemia virus type 1 (HTLV-1) causes both neoplastic and inflammatory diseases,
including adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Because
these life-threatening and disabling diseases are not yet curable, it is important to prevent new HTLV-1 infections.
Findings: In this study, we have established a simple humanized mouse model of HTLV-1 infection for evaluating
prophylactic and therapeutic interventions. In this model, HTLV-1-negative normal human peripheral blood
mononuclear cells (PBMCs) are transplanted directly into the spleens of severely immunodeficient NOD-SCID/γcnull
(NOG) mice, together with mitomycin-treated HTLV-1-producing T cells. Using this model, we tested the efficacy of
monoclonal antibodies (mAbs) specific to HTLV-1 as well as human IgG isolated from HAM/TSP patients (HAM-IgG)
in preventing HTLV-1-infection. One hour before and 24 h after transplantation of the human cells, each antibody
sample was inoculated intraperitoneally. On day 14, human PBMCs isolated from the mouse spleens were tested for
HTLV-1 infection. Whereas fresh CD4-positive and CD8-positive T cells isolated from untreated mice or mice treated
with isotype control mAb, HTLV-1 non-neutralizing mAbs to envelope gp46, gag p19, and normal human IgG
were all infected with HTLV-1; the mice treated with either HTLV-1 neutralizing anti-gp46 mAb or HAM-IgG did not
become infected.
Conclusions: Our data indicate that the neutralizing function of the antibody, but not the antigen specificity, is
essential for preventing the in vivo transmission of HTLV-1. The present animal model will also be useful for the
in vivo evaluation of the efficacy of candidate molecules to be used as prophylactic and therapeutic intervention
against HTLV-1 infection.
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Human T cell leukemia virus type-1 (HTLV-1) has been
linked to the development of adult T-cell leukemia
(ATL) and a chronic inflammatory disease called HTLV-
1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) [1]. However, the mechanism of disease* Correspondence: mineki@med.kawasaki-m.ac.jp
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unless otherwise stated.pathophysiology is still incompletely understood, and
the treatments available are still unsatisfactory. Therefore,
studies should be conducted to develop an effective
method for preventing the occurrence of new infections,
as well as to identify the mechanism of disease develop-
ment and effective treatment following infection. This will
require the development of a small animal model that can
be exploited as a tool for the screening and evaluation of
HTLV-1 infection. However, although HTLV-1 consist-
ently infects rabbits [2,3], some non-human primates
[4,5], and to a lesser extent, rats [6,7], the virus does notd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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indicated that viral transmission in mice, using typical
methods of infection, results in inconsistent infections
and limited virus expression in tissues [8-10].
Here we established a novel mouse model to evaluate
primary HTLV-1 infection of human lymphocytes in vivo.
In this model, HTLV-1-negative healthy human peripheral
blood mononuclear cells (PBMCs) (2 × 106/mouse) were
transplanted directly into the spleens of severely immuno-
deficient NOD-SCID/γcnull (NOG) mice, together with
cells from the mitomycin C (MMC)-treated HTLV-1-
infected cell line ILT-M1 (1 × 106/mouse), which is an IL-
2-dependent CD8+ T cell line derived from a HAM/TSP
patient (kindly provided by Prof. Kannagi of Tokyo Med-
ical and Dental University). Cell suspensions in a final vol-
ume of 50 μl were administered by intrasplenic injection
(hereafter called hu-PBMC-NOG-spl mice). As previously
reported [11], the severe immune deficiency of the NOG
strain enables efficient engraftment of the human T cells,
and a reduction in mouse death caused by severe
graft-versus-host disease (GVHD), compared to those
inoculated into the peritoneal cavity, which is the more
common route of administration. In fact, all mice grew
normally without piloerection or weight loss until 14 days
after transplantation (i.e., the time of sacrifice).
First, we isolated the bulk spleen cells from hu-PBMC-
NOG-spl mice sacrificed 14 days post inoculation/infec-
tion. Using flow cytometry (FCM), live cells were gated
on their forward and side light scatter characteristics,
and cell surface markers within the HLA-class I-positive
population (i.e., human cells) were analyzed (Figure 1A).
The numbers of recovered human cells (i.e. HLA-class I
positive cells) from the mouse spleens were 1.48 × 107
(Donor #1), 1.29 × 107 (Donor #2) and 1.92 × 107 (Donor
#3), respectively, which are much higher than the num-
bers of inoculated human cells, suggesting successful
engraftment. The increased numbers of human T cells in
the mouse spleens within two weeks after inoculation may
have been caused by xenoreactive lymphocyte prolifera-
tion, since recent report by Søndergaard et al. suggested
that injection of human PBMCs into NOG mice cause
polyclonal expansion and activation of functional
human T cells [12]. Meanwhile, human T cell expansion
due to HTLV-1 is unlikely, since there is no clear differ-
ence in numbers of human T cells in the mouse spleens
between mice treated with PBS (i.e., HTLV-1-infected)
and mice treated with neutralizing antibodies (i.e.,
HTLV-1-uninfected) (data not shown). There tended to
be higher frequencies of CD4-positive cells than CD8-
positive cells (Figure 1B). Next, in order to confirm
HTLV-1 infection, we isolated human CD4- and CD8-
positive T cells by positive immunoselection from the
bulk spleen cells, and then amplified a fragment of the
HTLV-1 pX region by genomic PCR (Figure 1C). Asshown in Figure 1C, similar to the naturally HTLV-1-
infected PBMCs from healthy carriers and HAM/TSP
patients, an HTLV-1 proviral DNA band was detected
in all the isolated human CD4- and CD8-positive cell
samples tested. We also performed RT-PCR in order to
detect viral mRNA (tax and HBZ) in these human CD4-
and CD8-positive T cells. As shown, all of the CD4 and
CD8 cells tested expressed both tax and HBZ mRNA
(Figure 1D). The poor visibility of tax mRNA bands of
CD8 cells suggest that the possible contamination of
residual ILT-M1 cells, which are positive for CD8 and
strongly express tax mRNA, is unlikely. To further rule
out the possible contamination of residual ILT-M1 cells,
inverse PCR amplification was carried out to determine
the sequences adjacent to HTLV-1 LTRs (both 3′- and
5′-LTR) using the DNA extracted from ILT-M1 cells, as
previously described [13]. Next, integration site-specific
PCR was carried out using primer pairs that encompass
HTLV-1 LTRs (both 3′- and 5′-LTR) and flanking host
sequences (Additional file 1: Table S1). As shown in
Additional file 2: Figure S1, no integration site-specific
bands were observed except for ILT-M1 cells, suggesting
that the possible contamination of HTLV-1 genome de-
rived from the residual ILT-M1 cells is unlikely. The me-
dian proviral DNA copy numbers (proviral load: PVL) in
1 × 104 of both the human CD4 and human CD8 cells re-
covered from three hu-PBMC-NOG-spl mice, each inocu-
lated with human PBMCs from different donors, were
9,533 and 4,546, respectively (i.e., 0.95 and 0.45 copies/
cell, respectively), suggesting highly efficient cell-to-cell
transmission of HTLV-1 from infected to uninfected
human lymphocytes in vivo. Although a previous study
also showed the successful engraftment of an HTLV-1-
transformed cell line and uninfected PBMCs in NOG
mice, the HTLV-1 PVL in spleen was very low and less
than 1% of cells were infected with HTLV-1 [14]. In this
previous study, 107 uninfected human PBMCs were
injected intraperitoneally, and those PBMCs were
infected with HTLV-1 by intraperitoneal inoculation of
MMC-treated HTLV-1-infected MT-2 cells (103 or 104
cells/mouse) [14]. The different infection efficiencies be-
tween the previous and present studies clearly indicate that
the efficient engraftment of the human Tcells in vivo could
be achieved by this route of inoculation. As shown in the
present study, an intrasplenic transfer of human PBMCs
can reduce the number of PBMCs required for the initial
inoculation by approximately 1 log unit for the generation
of more than 107 human T cells within two weeks, prob-
ably because human lymphocytes directly inoculated
into the mouse spleen are efficiently activated, and thus
HTLV-1 could efficiently infect human T cells in vivo. The
microanatomic environment of the secondary lymphoid
organs, such as the spleen, might also play an important






Figure 1 In vivo infection of HTLV-1 in engrafted human PBMCs in hu-PBMC-NOG-spl mice. A. Live cells were gated on their forward and
side light scatter characteristics, and then cell surface markers within the HLA-class I-positive population were analyzed. B. There tended to be
higher frequencies of CD4-positive cells than CD8-positive cells. The numbers represent the percentage of the cell population within the
HLA-class I-positive gate. C. Genomic PCR to confirm HTLV-1 infection. Genomic DNA was extracted from human CD4 and CD8-positive T cells
recovered from the spleens of hu-PBMC-NOG-spl mice sacrificed 14 days post infection, and then a fragment of the HTLV-1 pX region was
amplified. β-actin was used as a control. The lower limit of detection was one copy of HTLV-1 tax per 104 PBMCs. D. RT-PCR to confirm HTLV-1
infection. RNA was extracted from human CD4 and CD8-positive T cells recovered from the spleens of hu-PBMC-NOG-spl mice sacrificed
14 days post infection. cDNA was synthesized and amplified from HTLV-1 tax and the HBZ region as described previously [15]. GAPDH was used
as a control.
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in vivo is suppressed in the PBMCs of most HTLV-1-
infected individuals [16]. To test whether this phenomenon
occurs even in hu-PBMC-NOG-spl mice, we examined
HTLV-1 transactivator Tax protein expression in fresh and
cultured human lymphocytes recovered from the spleens
of infected hu-PBMC-NOG-spl mice by FCM. Similar to
naturally HTLV-1-infected cells from healthy carriers and
HAM/TSP patients [16], the fresh human lymphocytesrecovered from the mouse spleens expressed very low
levels of Tax protein (Figure 2A, upper panel). However,
Tax expression was rapidly induced after short-term
(16 h) cultivation ex vivo (Figure 2A, lower panel). Fur-
thermore, these Tax-expressing CD4-positive cells were
more frequently positive for chemokine (C-C motif )
receptor 4 (CCR4) than Tax-negative CD4-positive cells
(Figure 2B), as previously reported in natural HTLV-1
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Figure 2 Characteristics of HTLV-1-infected human T cells recovered from hu-PBMC-NOG-spl mice. Tax protein expression in human
lymphocytes recovered from the spleens of hu-PBMC-NOG-spl mice by flow cytometry. A. Human lymphocytes recovered from mouse spleens
express very low levels of Tax protein (upper panel). After a short-term (16 h) cultivation ex vivo, Tax expression was rapidly induced (lower panel).
The numbers represent the percentage of the Tax-positive cell population within the HLA-class I-positive gate. B. Tax-expressing cells are more
frequently positive for CCR4 than Tax-negative cells.
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infected with HTLV-1, the number of Tax positive cells
after ex vivo culture appeared to be small. This observa-
tion might be attributed to the culture conditions of this
experiment. Specifically, we cultured whole cells iso-
lated from the recipient mouse spleens, indicating themixed cultures of inoculated human PBMCs and mouse
cells including stromal cells. Recently, Kinpara et al.
reported that expression of HTLV-1 in HTLV-1-infected
T cells is markedly suppressed at both the mRNA and
protein levels upon co-culture of human cells and
mouse stromal cells, in part via the type I interferon
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observed small number of Tax-expressing cells after
ex vivo culture is likely due to co-culture with mouse
stromal cells derived from the spleen. Meanwhile, we
observed that the percentage of Tax-expressing cells in
the same culture conditions varies from one patient to
another even in HAM/TSP patients with similar PVL
(Saito et al., unpublished data). Furthermore, the severely
immune-deficient NOG mice used in this study do not
have any acquired immune response against inoculated
HTLV-1 infected cells, such as HTLV-1-specific Abs,
helper T cells, and cytotoxic T lymphocytes. These obser-
vations suggest that not only culture conditions but also
cellular factors might be involved in the number of Tax-
expressing cells. It also needs to be clarified whether the
small number of Tax-expressing cells can be explained by
multiple infection of single cell. Further investigations of
such factors would be important for controlling HTLV-1
infection and disease development in vivo.
It is well established that the HTLV-1 virions are not
very infectious, and thus cell-to-cell transmission is more
efficient both in vivo and in vitro [20,21]. The surface
glycoproteins of HTLV-1, which are recognized by neu-
tralizing antibodies, play important roles in cell-to-cell
transmission [22,23]. Indeed, previous reports have indi-
cated that passive transfer of HTLV-1 Env-specific-
neutralizing antibodies is effective in preventing in vivo
infection in macaques [5,24] and rabbit [25,26] models.
However, these studies evaluated the in vivo transmis-
sion of HTLV-1 to non-human cells, which are more
resistant to HTLV-1 infection than human cells are. In
this study, we tested the protective efficacy of various
anti-HTLV-1 antibodies against HTLV-1 transmission
into human lymphocytes in vivo in the hu-PBMC-NOG-
spl mouse model. The mice immunized with the anti-
HTLV-1 gp46 neutralizing mAb (clone LAT-27) were
completely protected against HTLV-1 infection whereas
other non-neutralizing antibodies such as anti-gp46 mAb
(clone LAT-25), anti-Gag (clone GIN-7), anti-HCV (clone
MO-8), and anti-OX40 mAb (clone B-7B5) did not pro-
tect against infection (Figure 3A). The HTLV-1 proviral
DNA was not detected by quantitative real-time PCR in
the human lymphocytes recovered from hu-PBMC-NOG-
spl mice that received passive transfer of LAT-27, indicat-
ing that the neutralizing function is an essential factor in
preventing in vivo HTLV-1 transmission. Furthermore,
passive immunization with human polyclonal anti-HTLV-
1 IgG from HAM/TSP patients (HAM-IgG) can also pro-
tect against HTLV-1 infection in vivo, whereas human
immunoglobulin isolated from HTLV-1-negative donors
(NC-IgG) did not (Figure 3A). Consistent with the
results of the quantitative real-time PCR, FCM studies
also showed that the human CD4-positive cells recov-
ered from mouse spleens immunized with eitherLAT-27 or HAM-IgG, express only trace amounts of Tax
protein after short-term (16 h) cultivation ex vivo, which
may be the result of background false-positive staining. In
contrast, a significant amount of Tax protein was expressed
in human lymphocytes recovered from non-immunized
mouse spleens (PBS-injected) or mouse spleens immu-
nized with NC-IgG (Figure 3B). These results demonstrate
the requirement for the neutralizing function of the anti-
HTLV-1 antibody in preventing in vivo transmission. It is
noteworthy that neutralizing anti-Env gp46 clone LAT-27
and HAM-IgG completely blocked the in vivo transmis-
sion of HTLV-1 in human lymphocytes, even in the con-
ditions that permit the vigorous proliferation of human
lymphocytes that enables HTLV-1 to rapidly spread by
cell-to-cell contact. However, antibody injection only once
after PBMC transplantation did not block the HTLV-1
infection in vivo, suggesting that the pre-existing neutral-
izing anti-Env Abs are critical for preventing HTLV-1
infection (Additional file 3: Figure S2). This result also
suggests that in vivo transmission is established within
24 hours after transfer of HTLV-1-infected cells. Im-
portantly, although neutralizing Abs used in this study
displayed antibody-dependent cell-mediated cytotoxicity
(ADCC) activity in vitro in our previous study [27], such
neutralizing and ADCC activities of anti-Env Abs are not
crucial for the elimination of HTLV-1-infected cells once
HTLV-1 infection is established in vivo. Indeed, titers of
existing neutralizing and ADCC Abs did not correlate
with HTLV-1 PVL (i.e., numbers of HTLV-1-infected cells
in vivo) (Saito et al., unpublished data). Moreover, HAM/
TSP patients also showed high titers of such Abs, indi-
cating that these Abs are not potent in preventing the
onset of HAM/TSP in infected individuals. These data
also indicate the importance of passive immunization
before infection.
Recently, we reported that both LAT-27 and HAM-
IgG, but not non-neutralizing LAT-25 and NC-IgG, are
capable of depleting and/or eliminating HTLV-1-infected
cells in the presence of autologous PBMCs in vitro. This
occurs in part via ADCC, preventing the spontaneous
immortalization of T cells [27]. Thus, the neutralizing ac-
tivity is essential for preventing HTLV-1 infection as well
as malignant transformation. In the present study, al-
though non-neutralizing anti-Env gp46 (clone LAT-25)
and anti-Gag p19 (clone GIN-7), as well as control anti-
bodies (anti-HCV clone MO-8, anti-OX40 clone B-7B5),
and normal human IgG (NC-IgG) did not completely
block the infection, we observed that non-neutralizing
LAT-25 mAb and anti-OX40 mAb decreased the number
of HTLV-1 infected cells to some extent (Figure 3A). Since
OX40 is a cell-surface molecule specifically expressed on
HTLV-1-infected and activated T cells [28], and LAT-25
recognizes the HTLV-1 Env protein, these data may























Figure 3 HTLV-1 infection in hu-PBMC-NOG-spl mice was completely inhibited by neutralizing, but not non-neutralizing, antibodies. In
vivo transmission of HTLV-1 and protective efficacy of various monoclonal antibodies was evaluated using quantitative real-time PCR analysis of
HTLV-1 proviral DNA. Genomic DNA was extracted from the human lymphocytes recovered from hu-PBMC-NOG-spl mice. A. All of the mice
immunized with neutralizing mAbs against Env (clone LAT-27) were completely protected against HTLV-1 infection, whereas non-neutralizing
mAbs against Env (clone LAT-25), anti-Gag (clone GIN-7), anti-HCV (clone MO-8), or anti-OX40 mAb (clone B-7B5) did not protect against infection.
The mice immunized with human immunoglobulin isolated from HAM/TSP patients (HAM-IgG) were also protected against HTLV-1 infection,
whereas human IgG isolated from normal uninfected controls (NC-IgG) did not protect against infection. Results are shown as mean ± SE. To test
for significant differences among the different groups, one-way analysis of variance was performed, followed by Scheffe’s multiple comparisons
test. The lower limit of detection was one copy of HTLV-1 tax per 104 PBMCs. B. Flow cytometric studies indicated that the human lymphocytes
recovered from mouse spleens immunized with anti-Env neutralizing mAbs or HAM-IgG express only a trace amount of Tax protein after
short-term (16 h) cultivation ex vivo, which may be a background false-positive staining artifact. In contrast, a significant amount of Tax protein
was expressed in human lymphocytes recovered from non-immunized mouse spleens (PBS-injected) or mouse spleens immunized with NC-IgG.
The numbers represent the percentage of the cell population within the HLA-class I-positive/CD4-positive gate.
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or activated T cells in vivo. As shown in Figure 3A, human
IgGs isolated from uninfected people also suppressed the
PVL, indicating that the administered non-specific IgGs
also can help to eliminate the inoculated HTLV-1-infected
cells (i.e., ILT-M1 cells). It is well established that the
intravenous immunoglobulins (IVIg) therapy is effective in
various diseases including autoimmune diseases and life-
threatening infections. Although the precise mechanismof action of injected IVIg is not fully understood, several
pathophysiological mechanisms such as suppression of
idiotypic antibodies, saturation of Fc receptors on mac-
rophages, modulation of complement activation, and
suppression of various immunomodulators such as cy-
tokines, chemokines, and metalloproteinases have been
proposed [29]. It is therefore possible that the adminis-
tered non-specific immunoglobulin in our mouse model
also can help to eliminate the inoculated HTLV-1-infected
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ing in a decreased efficiency of in vivo infection.
In conclusion, we have established a novel and simple
small animal model to study primary HTLV-1 infection
in vivo. Although our mouse model is not the animal
models of HAM/TSP or ATL, the present study has
demonstrated an important rational basis for passive
immunization against HTLV-1 infection in humans.
Using our mouse model, in vivo evaluation of the
efficacy of drug candidates could also be investigated in
future studies.
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Additional file 1: Table S1. Sequences flanking the integration site of
HTLV-1 provirus in ILT-M1 cell and primer sequences used for integration
site-specific PCR.
Additional file 2: Figure S1. To rule out the possible contamination
of residual ILT-M1 cells, inverse PCR amplification was carried out to
determine the sequences adjacent to HTLV-1 LTRs (both 3′- and 5′-LTR)
using the DNA extracted from ILT-M1 cells, as previously described [13].
Then, integration site-specific PCR was carried out using primer pairs that
encompass HTLV-1 LTRs (both 3′ and 5′ LTR) and flanking host sequences
(Additional file 1: Table S1). As shown, no integration site specific bands
were observed except for ILT-M1 cells, suggesting that the possible
contamination of HTLV-1 genome derived from the residual ILT-M1 cells
is unlikely.
Additional file 3: Figure S2. Flow cytometric studies showed that the
human lymphocytes recovered from mouse spleens express the amount
of Tax protein after short-term (16 h) cultivation ex vivo, indicating that
the neutralizing anti-Env Ab (clone LAT-27) injection once after PBMC
transplantation did not block the in vivo transmission of HTLV-1.
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